{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T13:20:54Z","timestamp":1770988854847,"version":"3.50.1"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"published-print":{"date-parts":[[2010,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>To retrospectively review the incidence, treatment efficacy, we followed up newly diagnosed chronic myelogenous leukemia (CML) patients residing in Shanghai during 2001-2006.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>All eligible cases were reviewed with the data of efficacy responses as well as overall survival (OS) and progression-free survival (PFS) time.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>A total of 615 cases entered the study. CML mainly afflicted those aged 40-60 years old and was slightly more frequent in males than females. More than 85% of the patients were in chronic phase (CP) when diagnosed. All patients were divided into four groups based on the main regimens - hydroxyurea, interferon alpha (IFN-\u03b1), imatinib, and hemopoietic stem cell transplantation (HSCT). With the median follow-up of 18 months, imatinib treatment induced 92.2% complete hematologic responses, and 64.3% complete cytogenetic responses among CML-CP patients. Overall the therapeutic efficacy in the imatinib group was higher than that in the hydroxyurea or IFN-\u03b1 group. Meanwhile, in the imatinib group, all response rates of patients in CP were significantly greater than that in accelerated or blastic crisis phase. The patients treated with imatinib also showed the most promising results regarding OS and PFS. Patients receiving HSCT decreased markedly in number with the introduction of imatinib.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>The number of new patients arising in Shanghai increased from 2001 to 2006. There were still patients receiving hydroxyurea and IFN-\u03b1. As the first-line regime for CML, imatinib was less administered in Shanghai before, but has received considerable development and great responses since 2003.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1756-9966-29-20","type":"journal-article","created":{"date-parts":[[2010,3,3]],"date-time":"2010-03-03T19:14:47Z","timestamp":1267643687000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Summary of 615 patients of chronic myeloid leukemia in Shanghai from 2001 to 2006"],"prefix":"10.1186","volume":"29","author":[{"given":"Ai-Hua","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan-Yan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Yao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zi-Zhen","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhi-Xiang","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiong","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun-Min","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,3,3]]},"reference":[{"key":"267_CR1","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/243290a0","volume":"243","author":"JD Rowley","year":"1973","unstructured":"Rowley JD: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature. 1973, 243: 290-293. 10.1038\/243290a0.","journal-title":"Nature"},{"issue":"4944","key":"267_CR2","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1126\/science.2406902","volume":"247","author":"GQ Daley","year":"1990","unstructured":"Daley GQ, Van Etten RA, Baltimore D: Induction of chronic myelogenous leukemia in mice by the P210 bcr\/abl gene of the Philadelphia chromosome. Science. 1990, 247 (4944): 824-830. 10.1126\/science.2406902.","journal-title":"Science"},{"issue":"1","key":"267_CR3","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1517\/13543784.14.1.89","volume":"14","author":"SA Doggrell","year":"2005","unstructured":"Doggrell SA: BMS-354825: a novel drug with potential for the treatment of imatinib-resistant chronic myeloid leukaemia. Expert Opin Investig Drugs. 2005, 14 (1): 89-91. 10.1517\/13543784.14.1.89.","journal-title":"Expert Opin Investig Drugs"},{"issue":"2","key":"267_CR4","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.ccr.2005.01.007","volume":"7","author":"E Weisberg","year":"2005","unstructured":"Weisberg E, Manley PW, Breinstein W, Br\u00fcggen J, Cowan-Jacob SW, Ray A, et al: Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell. 2005, 7 (2): 129-141. 10.1016\/j.ccr.2005.01.007.","journal-title":"Cancer Cell"},{"key":"267_CR5","volume-title":"Common toxicity criteria, version 2.0","author":"Cancer Therapy Evaluation Program","year":"1998","unstructured":"Cancer Therapy Evaluation Program: Common toxicity criteria, version 2.0. 1998, Bethesda, Md. National Cancer Institute, March"},{"issue":"5","key":"267_CR6","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/S0002-9343(96)00061-7","volume":"100","author":"JE Cortes","year":"1996","unstructured":"Cortes JE, Talpaz M, Kantarjian H: Chronic myelogenous leukemia: a review. Am J Med. 1996, 100 (5): 555-570. 10.1016\/S0002-9343(96)00061-7.","journal-title":"Am J Med"},{"issue":"9","key":"267_CR7","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1056\/NEJMoa011573","volume":"346","author":"H Kantarjian","year":"2002","unstructured":"Kantarjian H, Sawyers C, Hochhars A, Guilhot F, Schiffer C, Gambacorti-Passerini C, et al: Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med. 2002, 346 (9): 645-652. 10.1056\/NEJMoa011573.","journal-title":"N Engl J Med"},{"issue":"23","key":"267_CR8","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1056\/NEJMoa062867","volume":"355","author":"BJ Druker","year":"2006","unstructured":"Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N, et al: Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006, 355 (23): 2408-2417. 10.1056\/NEJMoa062867.","journal-title":"N Engl J Med"},{"issue":"5531","key":"267_CR9","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1126\/science.1062538","volume":"293","author":"ME Gorre","year":"2001","unstructured":"Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, Sawyers CL: Clinical resistance to STI571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science. 2001, 293 (5531): 876-880. 10.1126\/science.1062538.","journal-title":"Science"},{"issue":"3","key":"267_CR10","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1016\/j.bbrc.2004.08.169","volume":"323","author":"N Sorel","year":"2004","unstructured":"Sorel N, Bonnet ML, Guillier M, Guilhot F, Brizard A, Turhan AG: Evidence of ABL-kinase domain mutations in highly purified primitive stem cell populations of patients with chronic myelogenous leukemia. Biochem Biophys Res Commun. 2004, 323 (3): 728-730. 10.1016\/j.bbrc.2004.08.169.","journal-title":"Biochem Biophys Res Commun"},{"issue":"5","key":"267_CR11","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1182\/blood-2002-03-0777","volume":"100","author":"ME O'Dwyer","year":"2002","unstructured":"O'Dwyer ME, Mauro MJ, Kurilik G, Mori M, Balleisen S, Olson S, et al: The impact of clonal evolution on response to imatinib mesylate (STI571) in accelerated phase CML. Blood. 2002, 100 (5): 1628-1633. 10.1182\/blood-2002-03-0777.","journal-title":"Blood"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1756-9966-29-20.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T04:51:02Z","timestamp":1630471862000},"score":1,"resource":{"primary":{"URL":"https:\/\/jeccr.biomedcentral.com\/articles\/10.1186\/1756-9966-29-20"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,3,3]]},"references-count":11,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,12]]}},"alternative-id":["267"],"URL":"https:\/\/doi.org\/10.1186\/1756-9966-29-20","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,3,3]]},"assertion":[{"value":"28 October 2009","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2010","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2010","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"20"}}